Alcon Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Alcon ha aumentado sus beneficios a una tasa media anual de 60.5%, mientras que los beneficios de la industria de Medical Equipment han experimentado un crecimiento de 7.6% anual. Los ingresos han ido creciendo a una tasa media de 6.3% al año. La rentabilidad financiera de Alcon es de 4.7%, y sus márgenes netos son de 10.3%.

Información clave

60.5%

Tasa de crecimiento de los beneficios

60.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	11.1%
Tasa de crecimiento de los ingresos	6.3%
Rentabilidad financiera	4.7%
Margen neto	10.3%
Próxima actualización de resultados	14 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Alcon Inc.'s (VTX:ALC) Shareholders Might Be Looking For Exit

Apr 03

Here's Why Alcon (VTX:ALC) Has Caught The Eye Of Investors

Mar 21

Results: Alcon Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 01

There's Been No Shortage Of Growth Recently For Alcon's (VTX:ALC) Returns On Capital

Feb 13

Does Alcon (VTX:ALC) Have A Healthy Balance Sheet?

Dec 28

We Like These Underlying Return On Capital Trends At Alcon (VTX:ALC)

Oct 26

Does Alcon (VTX:ALC) Have A Healthy Balance Sheet?

Sep 15

Alcon's (VTX:ALC) Robust Earnings Are Supported By Other Strong Factors

Aug 24

Is Alcon (VTX:ALC) A Risky Investment?

Jun 11

Alcon Inc. (VTX:ALC) On The Verge Of Breaking Even

May 16

Analyst Estimates: Here's What Brokers Think Of Alcon Inc. (VTX:ALC) After Its Annual Report

Feb 25

Is Alcon (VTX:ALC) A Risky Investment?

Feb 11

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Alcon. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

SWX:ALC Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	9,455	974	3,209	845
30 Sep 23	9,274	450	3,177	837
30 Jun 23	9,085	362	3,141	795
31 Mar 23	8,880	341	3,112	759
31 Dec 22	8,717	335	3,068	723
30 Sep 22	8,695	571	3,131	684
30 Jun 22	8,657	457	3,145	706
31 Mar 22	8,550	460	3,125	703
31 Dec 21	8,291	376	3,076	703
30 Sep 21	8,082	332	2,980	706
30 Jun 21	7,818	183	2,884	680
31 Mar 21	6,922	-390	2,690	665
31 Dec 20	6,833	-531	2,694	675
30 Sep 20	6,806	-717	2,647	678
30 Jun 20	6,836	-636	2,662	702
31 Mar 20	7,525	-604	2,827	707
31 Dec 19	7,508	-656	2,802	690
30 Sep 19	7,386	-638	2,830	735
30 Jun 19	7,280	-779	2,827	688
31 Mar 19	7,177	-362	2,761	665
31 Dec 18	7,153	-227	2,799	653
30 Sep 18	7,123	175	2,725	527
31 Dec 17	6,792	256	2,596	545
31 Dec 16	6,596	-170	2,526	481
31 Dec 15	6,776	308	2,337	457

Ingresos de calidad: ALC tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (10.3%) de ALC son superiores a los del año pasado (3.8%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: ALC ha pasado a ser rentable en los últimos 5 años, con un crecimiento de los beneficios de 60.5% al año.

Acelerando crecimiento: El crecimiento de los beneficios de ALC en el último año (190.7%) supera su media de 5 años (60.5% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de ALC en el último año (190.7%) superó al de la industria Medical Equipment -7.1%.

Alcon Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings: EPS exceeds analyst expectations

Third quarter 2023 earnings: EPS exceeds analyst expectations

Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.30 in 2Q 2022)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS misses analyst expectations

Second quarter 2022 earnings: EPS exceeds analyst expectations

Recent updates

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and Its Hydrus Microstent for Microinvasive Glaucoma Surgery

Dividend of CHF0.24 announced

Alcon Inc.'s (VTX:ALC) Shareholders Might Be Looking For Exit

Alcon Announces Management Changes

Here's Why Alcon (VTX:ALC) Has Caught The Eye Of Investors

Alcon Inc. Launches Clareon Presbyopia Correcting IOLs in India

President of North America notifies of intention to sell stock

Results: Alcon Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Alcon Inc. Proposes Dividend for the Year 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Alcon Announces Positive Topline Results from Phase 3 Comet Trials of AR-15512, A Novel Topical Drug Candidate for Dry Eye

Alcon Inc.'s (VTX:ALC) Business Is Yet to Catch Up With Its Share Price

Returns On Capital Are Showing Encouraging Signs At Alcon (VTX:ALC)

Alcon Inc., Annual General Meeting, May 08, 2024

Alcon Inc. Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Calculating The Fair Value Of Alcon Inc. (VTX:ALC)

Alcon Inc. Showcases Cloud-Based Planning and World-Class Digital Technologies During AAO 2023

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Alcon Launches Total30 Multifocal Contact Lenses for Patients with Presbyopia

Alcon (VTX:ALC) Might Have The Makings Of A Multi-Bagger

Alcon Inc. Raises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.30 in 2Q 2022)

A Look At The Fair Value Of Alcon Inc. (VTX:ALC)

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Head of Corporate Development notifies of intention to sell stock

Investors Will Want Alcon's (VTX:ALC) Growth In ROCE To Persist

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alcon Inc. Provides Earnings Guidance for the Year 2023

Alcon Announces Results from a New Study Presented at the American Society of Cataract and Refractive Surgery Annual Meeting

Alcon Inc. Approves Dividend

Upcoming dividend of CHF0.21 per share at 0.3% yield

Does Alcon (VTX:ALC) Have A Healthy Balance Sheet?

Full year 2022 earnings: EPS misses analyst expectations

Now 21% undervalued

Alcon Inc. Announces Settlement of Litigation Related to Femtosecond Laser Assisted Cataract Surgery Devices

Alcon Launches New Total Toric Lenses for Astigmatic Patients

Here's Why Alcon (VTX:ALC) Has Caught The Eye Of Investors

Returns Are Gaining Momentum At Alcon (VTX:ALC)

Alcon Inc., Annual General Meeting, May 05, 2023

Alcon Introduces a Premium, Reusable Toric Lens with Launch of TOTAL30 for Astigmatism

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Now 20% undervalued

Alcon Inc. Updates Earnings Guidance for the Year 2022

Insufficient new directors

Alcon Inc. Revises Revenue Guidance for 2022

Do Alcon's (VTX:ALC) Earnings Warrant Your Attention?

Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022

Alcon's (VTX:ALC) Returns On Capital Are Heading Higher

We Think Alcon (VTX:ALC) Can Stay On Top Of Its Debt

With Alcon Inc. (VTX:ALC) It Looks Like You'll Get What You Pay For

Alcon Inc. (SWX:ALC) entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI) for approximately $770 million.

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations

Alcon Inc. Revises Revenue Guidance for 2022

These 4 Measures Indicate That Alcon (VTX:ALC) Is Using Debt Reasonably Well

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.

Alcon (VTX:ALC) Is Experiencing Growth In Returns On Capital

Alcon Inc. Reaffirms Earnings Guidance for the Fiscal 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Alcon Inc. Declares Dividend for 2021

Insufficient new directors

Alcon Announces Key Data to Be Presented at This Year’s American Society of Cataract and Refractive Surgery Meeting on its SMART Solutions for Cataract Surgery

Alcon Inc. Announces Launch of Clareon Portfolio in the U.S

Consensus EPS estimates increase by 12%

Full year 2021 earnings: EPS exceeds analyst expectations

Alcon Inc. Proposes Dividend

There's Been No Shortage Of Growth Recently For Alcon's (VTX:ALC) Returns On Capital

Desglose de ingresos y gastos
Beta